Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00298064|
Recruitment Status : Completed
First Posted : March 1, 2006
Last Update Posted : May 12, 2016
|Condition or disease||Intervention/treatment||Phase|
|Cervical Cancer Cervix||Genetic: Tissue Repository||Not Applicable|
This study is done to gather preliminary data for determining the best way to test EGFR expression in patients with cervical cancer who will receive treatment with EGFR inhibitors in the future.
This study is designed to obtain preliminary data of genomic and phenotypic alterations of the EGFR pathway in high grade cervical intraepithelial lesions (HG-SIL) and invasive cervical cancers (CC) to be used later for therapeutic guidance and to evaluate genomic (over-expression, amplification, point mutations, etc.) and phenotypic alterations of other transduction pathways interacting with the EGFR pathway.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||300 participants|
|Official Title:||Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer|
|Study Start Date :||December 2005|
|Actual Primary Completion Date :||February 2008|
|Actual Study Completion Date :||February 2008|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00298064
|United States, New Mexico|
|University of New Mexico|
|Albuquerque, New Mexico, United States, 87131|
|Principal Investigator:||Claire Verschraegen, MD||University of New Mexico|